| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Sanggenon D targets multiple biological pathways and enzymes. It is a potent inhibitor of pancreatic lipase (PL) with an IC50 of 0.77 μM. It also inhibits cyclooxygenase-2 (COX-2) activity. In inflammatory cells, Sanggenon D inhibits nitric oxide (NO) production from LPS-induced RAW 264.7 cells at concentrations >10 μM. This effect is mediated by the suppression of inducible nitric oxide synthase (iNOS) enzyme induction rather than direct inhibition of iNOS enzyme activity. Sanggenon D also acts as a GABA(A) receptor modulator and has been shown to inhibit the growth of Staphylococcus aureus by modulating the fatty acid biosynthesis system.
|
|---|---|
| ln Vitro |
In vitro, Sanggenon D demonstrates potent antioxidant activity. It inhibits pancreatic lipase (PL) with an IC50 of 0.77 μM, suggesting potential applications in obesity and lipid metabolism research. It also inhibits COX-2 activity. Sanggenon D inhibits NO production in LPS-induced RAW 264.7 cells at concentrations >10 μM. This anti-inflammatory activity is achieved through suppression of iNOS enzyme induction. Additionally, Sanggenon D has been shown to inhibit the proliferation of breast cancer cells and suppress metastasis by modulating key signaling pathways such as NF-κB and MAPK. Its antibacterial activity against Staphylococcus aureus is attributed to modulation of the fatty acid biosynthesis system.
|
| ln Vivo |
In vivo activity data for Sanggenon D is limited in publicly available literature. As a compound with potent anti-inflammatory and antioxidant properties in vitro, it is hypothesized to exhibit similar effects in animal models of inflammation and oxidative stress. Its inhibition of pancreatic lipase suggests potential for in vivo studies on obesity and fat absorption. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free enzyme assays, the inhibitory activity of Sanggenon D against pancreatic lipase (PL) can be measured using a standard lipase assay. The assay typically involves incubating varying concentrations of Sanggenon D with a fixed concentration of pancreatic lipase and a fluorogenic or chromogenic substrate, such as 4-methylumbelliferyl oleate. The rate of substrate hydrolysis, which is proportional to enzyme activity, is monitored by fluorescence. The IC50 value, representing the concentration required to inhibit 50% of the enzyme activity, is calculated from a dose-response curve. Similarly, its inhibition of COX-2 can be assessed using a commercially available COX-2 inhibitor screening assay kit.
|
| Cell Assay |
For in vitro cellular assays, the anti-inflammatory activity of Sanggenon D is commonly assessed in LPS-stimulated RAW 264.7 macrophage cells. Cells are seeded in multi-well plates and pre-incubated with varying concentrations of Sanggenon D before stimulation with LPS. After incubation for a specific period (e.g., 18-24 hours), the culture supernatants are collected to measure nitric oxide (NO) production using the Griess reagent. To determine whether the effect is due to direct iNOS inhibition or suppression of its induction, Western blot or qPCR can be used to measure iNOS protein and mRNA expression levels in cell lysates. Cell viability is assessed concurrently using MTT or similar assays to ensure that the reduction in NO is not due to cytotoxicity.
|
| Animal Protocol |
For in vivo studies, Sanggenon D could be administered orally or intraperitoneally in rodent models of inflammation or metabolic disorders. In a model of acute inflammation, such as carrageenan-induced paw edema, the compound's anti-inflammatory effect would be assessed by measuring paw volume at various time points post-administration. For studying its potential anti-obesity effects, it could be administered to mice on a high-fat diet, and endpoints would include body weight, adipose tissue mass, serum lipid levels, and fecal fat content to assess pancreatic lipase inhibition. In models of cancer, its anti-proliferative effects could be evaluated in xenograft models.
|
| ADME/Pharmacokinetics |
Sanggenon D (C40H36O11) has a molecular weight of approximately 692.7 g/mol. It is a Diels-Alder-type adduct and is typically supplied as a powder. Its solubility is limited in water but it is soluble in organic solvents such as DMSO and ethanol. For in vitro studies, stock solutions are generally prepared in DMSO. For in vivo administration, the compound can be formulated in suitable vehicles like a mixture of DMSO, PEG, and saline. Storage is recommended at -20°C, protected from light and moisture. Its stability, particularly in solution, has rarely been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available from comprehensive safety pharmacology or toxicology studies. As a natural flavonoid from a plant with a history of use, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that the observed effects are not due to a general reduction in cell viability. Further in vivo toxicological profiling, including acute and repeated-dose toxicity studies in rodents, would be necessary to establish a complete safety profile.
|
| References | |
| Additional Infomation |
Morigenin-C has been reportedly found in both Mongolian mulberry (Morus mongolica) and white mulberry (Morus alba), and relevant data are available.
See also: Morigenin-D (note moved to). Sanggenon D is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool and a reference standard for studying inflammation, oxidative stress, and metabolic pathways. Its mechanism of action involves the inhibition of pancreatic lipase and COX-2, modulation of the GABA(A) receptor, and suppression of iNOS induction. These diverse activities make it a promising lead for further drug discovery efforts targeting conditions like obesity, inflammation, and cancer. No clinical trials have been reported. |
| Molecular Formula |
C40H36O12
|
|---|---|
| Molecular Weight |
708.70664
|
| Exact Mass |
708.22
|
| CAS # |
81422-93-7
|
| PubChem CID |
13824422
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
999.3±65.0 °C at 760 mmHg
|
| Melting Point |
175-185℃
|
| Flash Point |
312.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.727
|
| LogP |
7.94
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
52
|
| Complexity |
1430
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C5=C(C=C4O)OC6(C7=C(C=C(C=C7)O)OC6(C5=O)CC=C(C)C)O)O
|
| InChi Key |
SUOXGDJCEWTZIZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C40H36O12/c1-18(2)10-11-39-38(49)35-32(52-40(39,50)27-9-6-22(43)16-31(27)51-39)17-30(46)34(37(35)48)26-13-19(3)12-25(23-7-4-20(41)14-28(23)44)33(26)36(47)24-8-5-21(42)15-29(24)45/h4-10,13-17,25-26,33,41-46,48,50H,11-12H2,1-3H3
|
| Chemical Name |
2-[6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-1,3,5a,8-tetrahydroxy-10a-(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~141.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4110 mL | 7.0551 mL | 14.1101 mL | |
| 5 mM | 0.2822 mL | 1.4110 mL | 2.8220 mL | |
| 10 mM | 0.1411 mL | 0.7055 mL | 1.4110 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
